AI Article Synopsis
- Pemafibrate is a new medication for dyslipidemia that may have nonlipid-related effects, and a sensitive method was developed to measure its levels.
- The LC-MS/MS assay showed great accuracy and sensitivity, with a limit of quantification (LOQ) of 0.05 ng/ml and a quick run time of just 6 minutes, outperforming earlier methods.
- This validated method was effectively used in a rat study with lower doses than previously tested, laying the groundwork for further research on pemafibrate's effects.
Article Abstract
Pemafibrate, a novel selective peroxisome proliferator-activated receptor-α modulator, is prescribed for patients with dyslipidemia. To investigate other potential nonlipid-related effects of pemafibrate, the sensitive and rapid quantitation method for pemafibrate was required. The developed LC-MS/MS assay method exhibited excellent accuracy, precision, sensitivity, stability, no matrix effect and high recovery. The LOQ (0.05 ng/ml) and run time (6.0 min) were superior to previous reports. The calibration curve showed good linearity over the wide concentration range (0.05-100.00 ng/ml). This validated method was successfully applied in a rat pharmacokinetic study using lower doses (0.02 or 0.10 mg/kg) than have been previously reported. This method can support gathering data for the evaluation of pemafibrate in future studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4155/bio-2020-0081 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!